ALNY
Alnylam Pharmaceuticals, Inc.
ALNY has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
ALNY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
ALNY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ALNY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 8x | $157 | — |
| Forward | 22x | $157 | — |
| Cheap | 41x | $800 | +411% |
| Fair | 76x | $1,489 | +851% |
| Expensive | 1,731x | $33,895 | +21538% |
Historical ranges are pointers, not guarantees.
ALNY has the edge over NVO in the historical PE scenario, which offers more potential upside but is not a forecast.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
ALNY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Limited | |
| Low |
ALNY has the edge over NVO on the outlook, with more favorable earnings expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ALNY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.04 | -64% |
| Q3 2026 | $19.58 | +8413% |
| Q2 2026 | $5.70 | +$8.18 |
| Q1 2026 | $3.98 | +$6.08 |
| Q4 2025 | $2.03 | +$4.21 |
| Q3 2025 | $0.23 | +$2.81 |
| Q2 2025 | -$2.48 | -$1.92 |
| Q1 2025 | -$2.10 | +$0.54 |
| Q4 2024 | -$2.18 | +$1.34 |
ALNY's earnings per share have jumped to their highest in seven years: $19.58 over the past year, up from $0.23 the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over ALNY on earnings, with more consistent year-over-year improvement.
ALNY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +17% |
| Q2 2026 | $1.3B | +67% |
| Q1 2026 | $1.2B | +96% |
| Q4 2025 | $1.1B | +85% |
| Q3 2025 | $1.2B | +149% |
| Q2 2025 | $773.7M | +17% |
| Q1 2025 | $594.2M | +20% |
| Q4 2024 | $593.2M | +35% |
ALNY has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | -5.7 points |
| Q2 2026 | 18% | +20 points |
| Q1 2026 | 23% | +20 points |
| Q4 2025 | 12% | +30 points |
| Q3 2025 | 29% | +45 points |
| Q2 2025 | -2.1% | -9.5 points |
| Q1 2025 | 3% | +12 points |
| Q4 2024 | -18% | +8.7 points |
ALNY's operating margin was 24% last quarter, down 5.7 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over ALNY on profitability, with a higher operating margin.
ALNY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $271.2M | -13% |
| Q2 2026 | $292M | +109% |
| Q1 2026 | $48.7M | +$176M |
| Q4 2025 | $140.3M | +$244M |
| Q3 2025 | $313M | +692% |
| Q2 2025 | $139.4M | +20% |
| Q1 2025 | -$127.3M | -$32.8M |
| Q4 2024 | -$103.8M | -$58.7M |
ALNY has burned cash in most quarters: $752M over the past year, about three times what it generated the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
ALNY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -241K shares |
| 1 year | +0.5% | +692K shares |
| 3 years | +5.1% | +6.7M shares |
| 5 years | +16% | +18.9M shares |
| Available history | +24% | +26.3M shares |
ALNY has 138M diluted shares, up 0.5% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over ALNY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ALNY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.7x | Net Cash |
| Q2 2026 | -1.6x | Net Cash |
| Q1 2026 | -2.1x | Net Cash |
| Q4 2025 | -3.0x | Net Cash |
| Q3 2025 | -4.6x | Net Cash |
| Q2 2024 | -6.1x | Net Cash |
ALNY has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ALNY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.6 | Oversold |
| Stochastic | 2.9 | Oversold |
ALNY's weekly RSI is 29 (oversold) and its Stochastic is 3 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ALNY PE vs Healthcare Sector
| Metric | ALNY | Sector median | Relative |
|---|---|---|---|
| PE | 8x | 26x | 69% below |
| PE % | 2 | 29 | 27 pts below |
ALNY has the edge over NVO on valuation relative to its sector.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ALNY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $205.2 | 24% below |
| 20 week MA | $233.7 | 33% below |
| 50 week MA | $293.0 | 47% below |
| 100 week MA | $314.6 | 50% below |
| 200 week MA | $257.7 | 39% below |
ALNY is in a downtrend: it's below all five of its weekly moving averages, and 39% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over ALNY on trend strength, trading above more of its moving averages.
ALNY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $117.5 | $137.6 | +17% |
| 2021 | $137.6 | $194.4 | +41% |
| 2022 | $194.4 | $237.9 | +22% |
| 2023 | $237.9 | $191.4 | -20% |
| 2024 | $191.4 | $238.0 | +24% |
| 2025 | $238.0 | $400.6 | +68% |
| 2026 YTD | $400.6 | $156.7 | -61% |
ALNY is down 61% so far in 2026, after finishing higher in five of the previous six years.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over ALNY on returns for 2026, with the stronger performance.